

Gynevia

α-GOS PREBIOTIC & LACTIC ACID



BACTERIAL VAGINOSIS MARKET NEED


BACTERIAL VAGINOSIS, THE KEY FIGURES

- + One of the most common & serious type of vaginal infections with a prevalence of **20% in women of reproductive age**
- + **High risk of relapses** after antibiotic therapy (metronidazole): > **50%** six months after the treatment*
- + The main risk factors are menstruations, antibiotics intake, sexual activity, pregnancy

Sources: * Bohbot & Lepargneur 2011

BACTERIAL VAGINOSIS, AN UNBALANCED VAGINAL FLORA

+ In bacterial vaginosis, the unbalance is in favor of the pathogen strain ***Gardnerella vaginalis*** associated with a pH increase while the main *Lactobacilli* are decreasing.



+ Bacterial vaginosis has a **strong impact on quality of life** with **bothersome symptoms** (vaginal discomfort, malodorous & debilitating vaginal discharge) and can even lead to miscarriage.

WOMEN'S EXPECTATIONS

What are women suffering from bacterial vaginosis looking for?

<p>EFFECTIVE To relieve the bothersome symptoms of BV</p>	<p>SUSTAINABLE To avoid relapses</p>	<p>SAFE For the pregnant women and their fetus</p>	<p>CONVENIENT Easy to apply</p>	<p>FAST To get rid of the unpleasant odour as quickly as possible</p>
----------------------------------------------------------------------	-------------------------------------------------	---------------------------------------------------------------	--------------------------------------------	----------------------------------------------------------------------------------



GYNEVIA, THE SCIENTIFIC INNOVATION IN THE TREATMENT OF BACTERIAL VAGINOSIS SYMPTOMS

- SPECIFIC & PATENTED α-GOS PREBIOTIC**
3 years of collaboration with the INRA have been required to develop **Gynevia's** complex prebiotic (α-GOS) able to promote the selective growth of resident *Lactobacilli* (good flora) to the detriment of pathogens bacteria in the vaginal flora.
- CLINICALLY PROVEN**
Gynevia treats bacterial vaginosis symptoms and stops relapses by durably restoring a normal pH and a balanced vaginal flora.
Gynevia eliminates malodorous vaginal discharge and relieves vaginal discomfort.
- SAFE & SUITABLE FOR PREGNANT WOMEN**
Bacterial vaginosis can cause complications during pregnancy (miscarriage).
The vaginal gel Gynevia can be safely used by pregnant women.
- CONVENIENT FORM**
The optimum viscosity of **Gynevia's** gel ensures a **consumer friendly application.**


Mode of action | See next page
Clinical studies




GYNEVIA HAS A SELECTIVE AFFINITY WITH THE HEALTHY VAGINAL BACTERIA

Resulting from extensive biochemistry and molecular engineering researches, **Gynevia's** α-GOS presents a **complex and highly polymerized chain of oligosaccharides** selectively digested by healthy *Lactobacilli* but NOT by pathogen strains.

Gynevia's affinity with the most representative vaginal *Lactobacilli* (*Lb. vaginalis*, *Lb. crispatus*, *Lb. jensenii*) vs low polymerized GOS (glucose).




Gynevia's affinity with pathogenic vaginal bacteria (*G. vaginalis*, *E. coli*, *C. albicans*) vs low polymerized GOS (glucose).



GYNEVIA, THE CLINICALLY PROVEN SOLUTION


The efficacy of **Gynevia** on bacterial vaginosis has been proven in 2 randomized, double-blind clinical studies including 97 women.

CLINICAL STUDY 1: Post antibiotic treatment (N=61)



100% of the women treated with Gynevia have retrieved a healthy vaginal flora (Nugent Score < 3) after 8 days of treatment while no evolution is measured in the placebo group.
Bacterial vaginosis recurrence is divided by 6 with the use of Gynevia after antibiotic therapy.

CLINICAL STUDY 2: Preventive treatment (N=36)



80.5% of women have not faced BV relapses within the 6 months following the end of the treatment.
Gynevia's preventive use durably restores vaginal balance, and thus stops bacterial vaginosis relapses

TECHNICAL INFORMATION

- + Actives: Patented α-GOS prebiotic, Red clover extract & Lactic acid
- + Regulatory: Medical device
- + Quality: Manufactured in EU following GMP and ISO 13485 standards
- + Recommended use: 1 dose per day, for 8 consecutive days
- + Presentation: Vaginal gel – 8 single doses

- ▶ **PATENTED & SPECIFIC α-GOS PREBIOTIC**
- ▶ **TREATMENT OF BV SYMPTOMS**
- ▶ **REDUCTION OF BV RELAPSES**

- ▶ **SUITABLE FOR PREGNANT WOMEN**
- ▶ **CLINICALLY PROVEN**



The method of Nugent is a microscopic examination of vaginal secretions. The presence and amounts of 3 bacterial morphotypes (*Lactobacilli*, *Gardnerella vaginalis*, *Mobiluncus* species) are assessed to diagnose a bacterial vaginosis. The Nugent score is classified as follows: 0-3 is considered negative for bacterial vaginosis (BV) / 4-6 is considered intermediate / 7+ is considered indicative of BV.